AR037484A1 - Un compuesto derivado de amino-triazolopiridina, un medicamento que contiene uno o mas de los compuestos, un proceso para la preparacion del compuesto y el uso del compuesto - Google Patents
Un compuesto derivado de amino-triazolopiridina, un medicamento que contiene uno o mas de los compuestos, un proceso para la preparacion del compuesto y el uso del compuestoInfo
- Publication number
- AR037484A1 AR037484A1 ARP000104612A ARP000104612A AR037484A1 AR 037484 A1 AR037484 A1 AR 037484A1 AR P000104612 A ARP000104612 A AR P000104612A AR P000104612 A ARP000104612 A AR P000104612A AR 037484 A1 AR037484 A1 AR 037484A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- lower alkyl
- halogen
- alkyl
- lower alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Compuesto derivado de amino-triazolopiridina de la fórmula (1), en donde: R1 es un grupo heteroarilo de 5 ó 6 miembros, que contiene entre 1 y 3 heteroátomos, seleccionados de entre N, O ó S, y cuyos grupos se encuentran opcionalmente sustituidos por uno o dos sustituyentes, los cuales son alquilo inferior; -(CH2)nOH, halógeno o alcoxi inferior, y en donde los grupos heteroarilo se pueden encontrar de forma opcional unidos al anillo de pirazol mediante un grupo alquileno o alquenilo o es fenilo, sustituido de forma opcional por uno o dos sustituyentes que son alquilo inferior, hidroxi-alquilo inferior, halógeno, hidroxi o alcoxi inferior o es -O(CH2)nfenilo, benzofurilo, indolilo o benzotiofenilo, o es -S-alquilo inferior; R2 y R4 son independientemente uno de otro hidrógeno, ciano o -S(O)2-fenilo; R3 es hidrógeno, halógeno o es un grupo heteroarilo de 5 ó 6 miembros, que contiene entre 1 y 3 heteroátomos, seleccionados de entre N, O ó S y cuyos grupos se encuentran sustituidos de forma opcional por uno o dos sustituyentes, los cuales son alquilo inferior, -(CH2)n-arilo, hidroxi, halógeno, alcoxi inferior, morfolinilo, amino, alquilamino inferior o -C(O)NR'2, y en donde R' es alquilo inferior o hidrógeno, o es fenilo, sustituido de forma opcional por uno o dos sustituyentes que son halógeno, alquilo inferior, alcoxi inferior, amino, di-alquilamino inferior, CF3, -OCF3, -NHC(O)alquilo inferior, ciano, -C(O)-alquilo inferior, -C(O)O-alquilo inferior, -S-alquilo inferior, -S(O)2NH-fenilo, -S(O)2-metilpiperazinilo; o es -NR'R'', en donde R' y R'' son independientemente uno de otro hidrógeno, -(CH2)nfenilo, cuyo anillo de fenilo se encuentra sustituido de forma opcional por halógeno o alcoxi inferior, -CH(alquilo inferior)-fenilo, indan-1-ilo, 1,2,3,4-tetrahidro-naftaleno, o cicloalquilo; o es -O-fenilo, cuyo anillo de fenilo se encuentra sustituido de forma opcional por halógeno, alquilo inferior o alcoxi inferior, -O-tetrahidronaftalenilo ó -O-CH2-6-metil-piridin-2-ilo; o es -benzo[1,3]dioxolilo, -1H-indol-5-ilo, naftilo, benzo-furan-2-ilo, 1,3,4,9-tetrahidro-b-carbolin-2-ilo, piperidin-1-ilo, pirrolidin-1-ilo, piperazin-4-il-metilo o morfolinilo; R5 es -NR2, en donde R pude ser el mismo o diferente y es hidrógeno, alquilo inferior, fenilo, bencilo, -CO-alquilo inferior, -CO-alcoxi inferior, -alquenilo inferior, -CO(CH2)n-fenilo o -COO(CH2)n-fenilo, en donde el anillo de fenilo se encuentra sustituido de forma opcional por CF3, alcoxi inferior, halógeno o alquilo inferior, -CO(CH2)3-NHCO-alcoxi inferior, -(CH2)n-fenilo, en donde el anillo de fenilo se encuentra sustituido de forma opcional por alcoxi inferior, CF3 o halógeno o es ácido 4,5-dihidro-1H-imidazol-2-il-benzóico, ácido 1,4,5,6-tetrahidro-pirimidin-2-il-benzóico o ácido 4,5,6,7-tetrahidro-1H-[1,3]diazepin-2-il-benzóico; n es 0-4 y sus sales farmacéuticamente aceptables. También se divulga un medicamento que contiene uno o más de los compuestos derivados de amino-triazolopiridina, un proceso para la preparación de un compuesto derivado de amino-triazolopiridina y el uso del compuesto para el tratamiento de enfermedades relacionadas con el receptor de adenosina A2A o para la elaboración de los medicamentos correspondientes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99117578 | 1999-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037484A1 true AR037484A1 (es) | 2004-11-17 |
Family
ID=8238933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000104612A AR037484A1 (es) | 1999-09-06 | 2000-09-04 | Un compuesto derivado de amino-triazolopiridina, un medicamento que contiene uno o mas de los compuestos, un proceso para la preparacion del compuesto y el uso del compuesto |
Country Status (22)
Country | Link |
---|---|
US (1) | US6355653B1 (es) |
EP (1) | EP1214322A2 (es) |
JP (1) | JP2003528811A (es) |
KR (1) | KR20020027625A (es) |
CN (1) | CN1379777A (es) |
AR (1) | AR037484A1 (es) |
AU (1) | AU7511000A (es) |
BR (1) | BR0013792A (es) |
CA (1) | CA2383998A1 (es) |
CZ (1) | CZ20021220A3 (es) |
HR (1) | HRP20020172A2 (es) |
HU (1) | HUP0203316A3 (es) |
IL (1) | IL148167A0 (es) |
MA (1) | MA26816A1 (es) |
MX (1) | MXPA02001748A (es) |
NO (1) | NO20021077L (es) |
PE (1) | PE20010629A1 (es) |
PL (1) | PL354240A1 (es) |
TR (1) | TR200200579T2 (es) |
WO (1) | WO2001017999A2 (es) |
YU (1) | YU13502A (es) |
ZA (1) | ZA200201055B (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506772B1 (en) | 2000-12-15 | 2003-01-14 | Hoffmann-La Roche Inc. | Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands |
US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
US6693116B2 (en) * | 2001-10-08 | 2004-02-17 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
PL370067A1 (en) * | 2001-10-08 | 2005-05-16 | F.Hoffmann-La Roche Ag | 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide |
EP1453836B1 (en) | 2001-11-30 | 2007-03-28 | Schering Corporation | BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS |
HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
EP2942082B1 (en) | 2002-01-28 | 2019-03-06 | Kyowa Hakko Kogyo Co., Ltd | A2a receptor antogonists for use in the treatment of movement disorders |
CA2489252A1 (en) * | 2002-06-13 | 2003-12-24 | Pfizer Inc. | Non-peptide gnrh agents, pharmaceutical compositions and methods for their use |
EP1711498A2 (en) * | 2004-01-26 | 2006-10-18 | Altana Pharma AG | 1,2,4-triazolo¬1,5-a|pyridines as gastric acid secretion inhibitors |
CA2591125A1 (en) * | 2004-12-21 | 2006-06-29 | Schering Corporation | Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
EP2081905B1 (en) * | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
JP5030114B2 (ja) * | 2006-09-25 | 2012-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体をモジュレートする化合物 |
JP2010510987A (ja) * | 2006-11-27 | 2010-04-08 | ハー・ルンドベック・アクチエゼルスカベット | ヘテロアリールアミド誘導体 |
JP2010511018A (ja) * | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物 |
BRPI0809567A2 (pt) * | 2007-04-10 | 2014-09-23 | Lundbeck & Co As H | Composto, composição farmacêutica, método para modular a atividade de um receptor de p2x7, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, e para determinar a presença ou ausência do receptor de p2x7 em uma amostra, preparação farmacêutica acondiciaonada, e, uso de um composto |
WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2217565B1 (en) * | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
CA2724232A1 (en) * | 2008-05-13 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
JP5595389B2 (ja) * | 2008-06-20 | 2014-09-24 | ジェネンテック, インコーポレイテッド | トリアゾロピリジンjak阻害剤化合物と方法 |
JP5512665B2 (ja) * | 2008-06-20 | 2014-06-04 | ジェネンテック, インコーポレイテッド | トリアゾロピリジンjak阻害剤化合物と方法 |
US8178568B2 (en) * | 2008-07-10 | 2012-05-15 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the CB2 receptor |
TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
KR20110063438A (ko) * | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Cb2 수용체를 선택적으로 조절하는 설포닐 화합물 |
MY153913A (en) * | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EP2438066A2 (en) | 2009-06-05 | 2012-04-11 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES |
US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8383615B2 (en) | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
AU2010271732B2 (en) * | 2009-07-17 | 2016-08-25 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer |
JP2013505295A (ja) * | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節する化合物 |
JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
JP5746228B2 (ja) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節するテトラゾール化合物 |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
CN103827114B (zh) * | 2011-09-19 | 2016-08-24 | 霍夫曼-拉罗奇有限公司 | 作为pde10a抑制剂的三唑并吡啶化合物 |
EP2757883B1 (en) * | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
WO2017157885A1 (de) | 2016-03-16 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel |
CN106543175B (zh) * | 2016-10-28 | 2018-06-01 | 上海大学 | 三芳基[1,2,4]三氮唑[1,5-a]吡啶衍生物及其制备方法 |
JP7111733B2 (ja) * | 2017-03-16 | 2022-08-02 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ヘテロアリール[4,3-c]ピリミジン-5-アミン誘導体、その製造方法、およびその医薬の使用 |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
EP3818063A1 (en) * | 2018-07-05 | 2021-05-12 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
WO2020054712A1 (ja) * | 2018-09-12 | 2020-03-19 | 日本化薬株式会社 | 有害生物防除剤 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
US20230167119A1 (en) * | 2021-01-09 | 2023-06-01 | Bugworks Research, Inc. | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2a receptor and adenosine 2b receptor antagonist |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9226735D0 (en) | 1992-12-22 | 1993-02-17 | Ici Plc | Azole derivatives |
AU2639299A (en) | 1998-02-24 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies/preventives for parkinson's disease |
-
2000
- 2000-08-24 US US09/645,127 patent/US6355653B1/en not_active Expired - Fee Related
- 2000-08-28 KR KR1020027002990A patent/KR20020027625A/ko not_active Application Discontinuation
- 2000-08-28 IL IL14816700A patent/IL148167A0/xx unknown
- 2000-08-28 CZ CZ20021220A patent/CZ20021220A3/cs unknown
- 2000-08-28 CN CN00812501A patent/CN1379777A/zh active Pending
- 2000-08-28 BR BR0013792-8A patent/BR0013792A/pt not_active IP Right Cessation
- 2000-08-28 PL PL00354240A patent/PL354240A1/xx not_active Application Discontinuation
- 2000-08-28 HU HU0203316A patent/HUP0203316A3/hu unknown
- 2000-08-28 JP JP2001522222A patent/JP2003528811A/ja active Pending
- 2000-08-28 WO PCT/EP2000/008372 patent/WO2001017999A2/en not_active Application Discontinuation
- 2000-08-28 AU AU75110/00A patent/AU7511000A/en not_active Abandoned
- 2000-08-28 MX MXPA02001748A patent/MXPA02001748A/es unknown
- 2000-08-28 TR TR2002/00579T patent/TR200200579T2/xx unknown
- 2000-08-28 CA CA002383998A patent/CA2383998A1/en not_active Abandoned
- 2000-08-28 YU YU13502A patent/YU13502A/sh unknown
- 2000-08-28 EP EP00964043A patent/EP1214322A2/en not_active Withdrawn
- 2000-09-04 AR ARP000104612A patent/AR037484A1/es not_active Application Discontinuation
- 2000-09-04 PE PE2000000903A patent/PE20010629A1/es not_active Application Discontinuation
-
2002
- 2002-02-06 ZA ZA200201055A patent/ZA200201055B/xx unknown
- 2002-02-26 HR HR20020172A patent/HRP20020172A2/hr not_active Application Discontinuation
- 2002-03-05 NO NO20021077A patent/NO20021077L/no not_active Application Discontinuation
- 2002-03-06 MA MA26540A patent/MA26816A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA02001748A (es) | 2002-08-06 |
CZ20021220A3 (cs) | 2002-10-16 |
PE20010629A1 (es) | 2001-05-30 |
TR200200579T2 (tr) | 2002-12-23 |
KR20020027625A (ko) | 2002-04-13 |
IL148167A0 (en) | 2002-09-12 |
JP2003528811A (ja) | 2003-09-30 |
NO20021077D0 (no) | 2002-03-05 |
AU7511000A (en) | 2001-04-10 |
YU13502A (sh) | 2004-11-25 |
WO2001017999A2 (en) | 2001-03-15 |
MA26816A1 (fr) | 2004-12-20 |
WO2001017999A3 (en) | 2001-12-06 |
CN1379777A (zh) | 2002-11-13 |
CA2383998A1 (en) | 2001-03-15 |
NO20021077L (no) | 2002-03-05 |
HUP0203316A2 (hu) | 2003-01-28 |
US6355653B1 (en) | 2002-03-12 |
EP1214322A2 (en) | 2002-06-19 |
PL354240A1 (en) | 2003-12-29 |
HUP0203316A3 (en) | 2004-07-28 |
ZA200201055B (en) | 2003-07-30 |
HRP20020172A2 (en) | 2003-10-31 |
BR0013792A (pt) | 2002-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR037484A1 (es) | Un compuesto derivado de amino-triazolopiridina, un medicamento que contiene uno o mas de los compuestos, un proceso para la preparacion del compuesto y el uso del compuesto | |
RU2324684C2 (ru) | Пиримидиновые производные | |
CN106103445B (zh) | 作为cdk抑制剂的吡唑并[1,5-a]嘧啶-5,7-二胺化合物和它们的治疗用途 | |
CN108348529A (zh) | 乙型肝炎核心蛋白调节剂 | |
AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
AR035665A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
DK0958296T3 (da) | Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme | |
BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
NO955074L (no) | 1-substituerte istain- og oksindolderivater som inhibitorer til acetylkolinesterase | |
AR009069A1 (es) | Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
SE8900192L (sv) | Dideoxididehydrokarbocykliska nukleosider | |
AR030203A1 (es) | Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario | |
DK0521768T3 (da) | Nye triazolopyrimidin-derivater som er angiotensin II-receptor-antagonister, fremgangsmåder til deres fremstilling og farmaceutiske præparater med indhold deraf | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
KR20060079098A (ko) | 신규한([1,3]티아졸로[5,4-b]피리딘-2-일)-2-카르복사마이드유도체 | |
RU95110762A (ru) | Производные 5-гидразинохинолона, композиция для лечения или профилактики инфекционного заболевания, способ лечения или профилактики | |
FI120403B (fi) | 4-(2-amino-6-(syklopropyyliamino)-9H-purin-9-yyli)-2-syklopenteeni-1-metanoli-sukkinaatti viruksia torjuvana aineena | |
HUP0302753A2 (hu) | Integrin inhibitor hatású karbamid- és uretánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
JP4299666B2 (ja) | Dnaプロテインキナーゼ阻害剤としてのチオピラン−4−オン類 | |
AR036735A1 (es) | Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina | |
AR040520A1 (es) | Derivados de pirazol heterociclicos condensados, como inhibidores de la quinasa | |
HUP0003962A2 (hu) | Kinuklidinil-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények, e vegyületek alkalmazása, valamint intermedierjeik | |
NO883263D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater. | |
CA3149302A1 (en) | Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |